Customising radiotherapy in stage II breast cancer after primary chemotherapy

Affiliations

¹ Department of Radiation Oncology, Institut Curie, Paris 75005, France. Electronic address: youlia.kirova@curie.fr.
² Department of Radiation Oncology, Institut Curie, Paris 75005, France.

Comment

Youlia Kirova et al. Lancet Oncol. 2022 Sep.

. 2022 Sep;23(9):1118-1119.

doi: 10.1016/S1470-2045(22)00496-X. Epub 2022 Aug 8.

¹ Department of Radiation Oncology, Institut Curie, Paris 75005, France. Electronic address: youlia.kirova@curie.fr.
² Department of Radiation Oncology, Institut Curie, Paris 75005, France.

No abstract available

Conflict of interest statement

We declare no competing interests.

De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study.
de Wild SR, de Munck L, Simons JM, Verloop J, van Dalen T, Elkhuizen PHM, Houben RMA, van Leeuwen AE, Linn SC, Pijnappel RM, Poortmans PMP, Strobbe LJA, Wesseling J, Voogd AC, Boersma LJ. de Wild SR, et al. Lancet Oncol. 2022 Sep;23(9):1201-1210. doi: 10.1016/S1470-2045(22)00482-X. Epub 2022 Aug 8. Lancet Oncol. 2022. PMID: 35952707